Titan Medical Inc. Announces Completion of Key Milestone in the Development of Its SPORT(TM) Surgical System

Titan Medical Inc. (the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) announced
today that it successfully completed animal tissue studies on May 30, 2014,
performing a full cholecystectomy (gallbladder removal) procedure using the
SPORT Surgical System alpha commercial prototype for the required surgical tasks
(including grasping, dissecting, mono-polar cautery and suturing). This comes
after the recent successful completion of the Q1 2014 milestone of completing an
alpha commercial prototype. "We are most pleased to confirm this key milestone
of the successful completion of an actual non-human surgical procedure. The
procedure was extensively validated by reviewing video footage of the surgical
field and instruments from several viewing angles," said John Hargrove, Titan
Medical Chairman and CEO. He further stated, "This is what we expected and
targeted for our goals-we have a great team, a great technology and a tremendous
opportunity. The development of the SPORT Surgical System remains on schedule."


About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD)(OTCQX:TITXF)
focused on the design and development of a robotic surgical system for
application in minimally invasive surgery ("MIS"). The Company's robotic
surgical system, currently under development, comprises a surgeon-controlled
robotic platform that includes a 3D vision system and interactive instruments
for performing MIS procedures, and a surgeon workstation that provides the
surgeon with an interface to the robotic platform for controlling the
interactive instruments and providing a 3D endoscopic view of inside a patient's
body during MIS procedures. The robotic surgical system is being designed to
expand robotic surgery into areas of surgical specialties and simple and complex
procedures that are currently under-serviced, and to allow surgeons to perform
procedures within small to medium size surgical spaces such as general surgery
and cholecystectomy. For more information, visit the Company's website at
www.titanmedicalinc.com.


Forward-Looking Statements

This news release contains "forward-looking statements" which reflect the
current expectations of management of the Company's future growth, results of
operations, performance and business prospects and opportunities. Wherever
possible, words such as "may", "would", "could", "will", "anticipate",
"believe", "plan", "expect", "intend", "estimate", "potential for" and similar
expressions have been used to identify these forward-looking statements. These
statements reflect management's current beliefs with respect to future events
and are based on information currently available to management. Forward-looking
statements involve significant risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements to
be materially different from any future results, performance or achievements
that may be expressed or implied by such forward-looking statements, including,
without limitation, those listed in the "Risk Factors" section of the Company's
Annual Information Form dated April 4, 2014 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties materialize,
or should assumptions underlying the forward looking statements prove incorrect,
actual results, performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in this news
release. These factors should be considered carefully and prospective investors
should not place undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based upon what
management currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or achievements
will be consistent with these forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Titan Medical Inc.
John T. Hargrove
Chairman and Chief Executive Officer
[phone] (ext. 151)
[e-mail]
www.titanmedicalinc.com